Demand For Oncology Biosimilars Is Anticipated To Surge Up At An Astronomical Pace, Registering A CAGR Of 11% By 2032

The market for oncology biosimilars is anticipated to surge up at an astronomical pace, registering a CAGR of 11% during the forecast period from, and 2022 to 2032. As of 2021, the market was valued at US$ 4 Billion, and is likely to rise at a Y-o-Y growth rate of 5% in 2022 to reach US$ 4.2 Billion. By the end of the forecast period, the industry is poised to reach US$ 12 Billion.

Read Report Overview: https://www.factmr.com/report/4800/oncology-biosimilars-market

Prominent Key players of the Oncology Biosimilars market survey report:

• Celltrion Inc.
• Dr. Reddy's Laboratories Ltd.
• Biocon
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmBh.
• Pfizer Inc.
• Celltrion Inc.
• Sandoz International GmBh
• STADA Arzneimittel AG
• Apotex Inc.

To remain 'ahead' of your competitors, request a sample:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4800

Key Segments Covered in the Oncology Biosimilars Industry Report

· Oncology Biosimilars by Drug
• G-CSF
• Monoclonal Antibody
• Hematopoietic Agents

· Oncology Biosimilars by Disease Indication

• Breast Cancer
• Non-Small Cell Lung Cancer
• Colorectal Cancer
• Neutropenia
• Blood Cancer
• Leukemia
• Myeloid Leukemia
• Chronic Lymphocytic Leukemia (CLL)
• Non-Hodgkin Lymphoma
• Others

· Oncology Biosimilars by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

· Oncology Biosimilars by Region

• North America
• Europe
• Asia Pacific
• Rest of the World

Speak To Research Analyst For Detailed Insights:
https://www.factmr.com/connectus/sample?flag=AE&rep_id=4800

Competitive Landscape

Celltrion, Inc., Dr. Reddy's Laboratories Ltd., Biocon, Teva Pharmaceutical Industries Ltd., and Sandoz International GmBH are the key participants in the worldwide oncology biosimilars market. As a result, it is a highly concentrated market. These market participants collectively account for more than 70% of the market share. To broaden their market footprints, these firms rely largely on active alliances to improve their product distribution networks.

• In 2018, Biocon, for example, established an exclusive global agreement with Sandoz on next-generation biosimilars. Similarly, Dr. Reddy's cooperated with TR Pharm in 2016 to offer three biosimilars in Turkey. Pfizer, Inc., Celltrion, Inc., Sandoz International GmBH, STADA Arzneimittel AG, and Apotex, Inc. are some of the other significant industry participants in the global oncology biosimilars market.

• Atos has announced recently in April 2022 that it intends to forge a 5-year contractual agreement to deliver managed services for digital operations, applications and cybersecurity for Independent Health (IH). Atos' operational solutions will leverage infrastructure and digital platforms to optimize operating costs and generate efficiencies across the business landscape.

Full Access of this Report Is Available at :-
https://www.factmr.com/checkout/4800

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email : sales@factmr.com
Blog: https://blog.factmr.com
Website : https://www.factmr.com

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range - from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analysed . Our sales offices in United States and Dublin, Ireland. Reach out to us with your goals, and we'll be an able research partner.

This release was published on openPR.